alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
HomeOffice of the SpokespersonPublic Schedule...Public Schedule – June 16, 2021

# 									Public Schedule – June 16, 2021							

Public Schedule

Office of the Spokesperson

June 15, 2021

*****THE DAILY PUBLIC SCHEDULE IS SUBJECT TO CHANGE*****

**SECRETARY ANTONY J. BLINKEN**

Secretary Blinken accompanies President Biden on travel to Cornwall, United Kingdom; Brussels, Belgium; and Geneva, Switzerland.  Please click here for more information.

**DEPUTY SECRETARY WENDY R. SHERMAN**Deputy Secretary Sherman attends meetings and briefings, from the Department of State.

**DEPUTY SECRETARY FOR MANAGEMENT AND RESOURCES BRIAN P. MCKEON**

Deputy Secretary McKeon attends meetings and briefings, from the Department of State.

**UNDER SECRETARY FOR POLITICAL AFFAIRS VICTORIA J. NULAND**

Under Secretary Nuland accompanies President Biden and Secretary Blinken on travel to Brussels, Belgium and Geneva, Switzerland.

**ACTING ASSISTANT SECRETARY FOR EUROPEAN AND EURASIAN AFFAIRS PHILIP T. REEKER**

**7:00 p.m.** Acting Assistant Secretary Reeker meets with Ukrainian Ambassador to United States Oksana Markarova, in Washington, D.C.**(CLOSED PRESS COVERAGE)**

**ACTING ASSISTANT SECRETARY FOR DEMOCRACY, HUMAN RIGHTS, AND LABOR LISA PETERSON**

Acting Assistant Secretary Peterson is on travel to Kinshasa, Democratic Republic of the Congo, from June 14-18, 2021.  Please click here for more information.

**ACTING ASSISTANT SECRETARY FOR INTERNATIONAL NARCOTICS AND LAW ENFORCEMENT AFFAIRS JAMES WALSH**

**1:00 p.m.** Acting Assistant Secretary Walsh participates virtually in a Center for Strategic and International Studies panel on “Renewing American Leadership in the Fight Against Corruption”, from the Department of State.  Please click here for more information.**(MEDIA DETERMINED BY HOST)**

**SPECIAL PRESIDENTIAL ENVOY FOR CLIMATE JOHN KERRY**

Special Presidential Envoy Kerry is on travel to the United Arab Emirates, Saudi Arabia, and Egypt, from June 13-17, 2021.

**BRIEFING SCHEDULE**

No Department Press Briefing

Tags

Office of the SpokespersonThe Secretary of State

Back to Top
#### MAYERCHAK REALTY COMPANY, a partnership, Appellant, v. SCOTT-VIA REALTY CORP., a New York Corporation, et al., Appellees.

No. 75-917.

District Court of Appeal of Florida, Third District.

Sept. 11, 1975.

PER CURIAM.

Appeal dismissed.
#### STATE of Louisiana v. Henry Peter HARRIS.

No. 62996.

Supreme Court of Louisiana.

Oct. 20, 1978.

In re: Henry Peter Harris, applying for supervisory writs of review, prohibition, mandamus and a stay order. Parish of East Baton Rouge.

Granted.

The petition of the relator in the above entitled and numbered case having been duly considered,

*915It is ordered that a writ of certiorari issue herein, directing the Honorable Douglas M. Gonzales, Judge of the Nineteenth Judicial District Court for the Parish of East Baton Rouge, to transmit to the Supreme Court of Louisiana, on or before the 3rd day of November, 1978, the record in duplicate, or a certified copy of the record in duplicate, of the proceedings complained of by the relator herein, to the end that the validity of said proceedings may be ascertained.

It is further ordered that the aforesaid Judge of said Court and the respondent through counsel shall show cause, in this court, on a date to be fixed by this court, at 10 o’clock A.M., why the relief prayed for in the petition of the relator should not be granted.
Court of Appeals

of the State of Georgia

ATLANTA,____________________

The Court of Appeals hereby passes the following order:

A16A1766. IN RE: ESTATE OF FRONICE S. PRICE.

In January 2015, Thomas L. Cohen, the administrator of the estate of Fronice

S. Price, filed an interim return covering the period of May 2014 to December 2014,

including a request for the payment of over $70,000 in legal fees. Two beneficiaries

of the estate objected that the estate’slegal fees were excessive. Following a hearing,

the probate court ordered payment of $11,580 in legal fees.

1 Cohen originally filed

his appeal in the Supreme Court, which transferred the case to this Court after finding

no basis for jurisdiction in the Supreme Court. We, however, also lack jurisdiction.

Cohen’s direct appeal is premature as there is no final judgment and the case

remains pending in the probate court. See OCGA § 5-6-34 (a) (1) (a judgment is final

“where the case is no longer pending in the court below”). Therefore, the order from

which Cohen seeks to appeal is interlocutory and not appealable without compliance

with the interlocutory appeal procedure of OCGA § 5-6-34 (b), which includes

obtaining a certificate of immediate review. See Bailey v. Bailey, 266 Ga. 832, 833

(471 SE2d 213) (1996). Cohen’s failure to follow the interlocutory appeal procedure

deprives us of jurisdiction, and this appeal is hereby DISMISSED.

Court of Appeals of the State of Georgia

Clerk’s Office, Atlanta,____________________

I certify that the above is a true extract from

the minutes of the Court of Appeals of Georgia.

Witness my signature and the seal of said court

hereto affixed the day and year last above written.

, Clerk.

1

 This case has previously been before this Court on an unrelated matter. See

Case No. A13A1517 (decided November 13, 2013). 

06/03/2016

June 03, 2016
§ 488.850 Directed plan of correction. ( a ) *Application.* CMS may impose a directed plan of correction when an HHA: ( 1 ) Has one or more deficiencies that warrant directing the HHA to take specific actions; or
( 2 ) Fails to submit an acceptable plan of correction.
( b ) *Procedures.* ( 1 ) Before imposing this sanction, CMS provides the HHA notice of the impending sanction.
( 2 ) CMS or the temporary manager (with CMS approval) may direct the HHA to take corrective action to achieve specific outcomes within specific timeframes.
( c ) *Duration and effect of sanction.* If the HHA fails to achieve compliance with the conditions of participation within the timeframes specified in the directed plan of correction, CMS: ( 1 ) May impose one or more other sanctions set forth in § 488.820; or
( 2 ) Terminates the provider agreement.
HomeKey Topics – Office of Ocean and Polar Affairs...Polar Affairs

# Polar Affairs

							Ocean & Polar Affairs Topics							

## 						The Office of Ocean and Polar Affairs (OPA): 					

develops and implements U.S. foreign policy as it relates to the Arctic region; and it also leads United States participation in the Arctic Council, an intergovernmental forum of the eight Arctic States. OPA also develops and coordinates U.S. policy affecting the Antarctic region, working to ensure that the Antarctic continues to be reserved for peace and science and to conserve marine life in the Southern Ocean.

## 					Discover More				

		Arctic Region		Read more 

		Antarctic Region		Read more 

		Other Important Arctic Links		Read more 

January 20, 2021		Office of Ocean and Polar Affairs		Read more 

Back to Top
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

NO. 03-22-00039-CV

In re Patrick Earl Tarkington

ORIGINAL PROCEEDING FROM COMAL COUNTY

M E M O R A N D U M O P I N I O N

Relator has filed a petition for writ of mandamus complaining of the trial court’s 

failure to rule on his motion to withdraw his attorney. Having reviewed the petition and the 

record provided, we deny the petition for writ of mandamus. See Tex. R. App. P. 52.8(a); see 

also Tex. R. App. P. 52.7(a); In re Smith, No. 03-14-00478-CV, 2014 WL 4079922, at *2 (Tex. 

App.—Austin Aug. 13, 2014, orig. proceeding) (denying mandamus relief when relator failed to 

provide sufficient record from which to evaluate claim for mandamus relief); In re Halley, 

No. 03-15-00310-CV, 2015 WL 4448831, at *2 (Tex. App.—Austin July 14, 2015) (orig. 

proceeding) (concluding that a six-month delay did not constitute an unreasonable length of time

under “failure to rule” analysis).
2

__________________________________________

Edward Smith, Justice

Before Chief Justice Byrne, Justices Kelly and Smith

Filed: February 11, 2022
§ 488.1110 Hospice program: surveys and hotline. ( a ) *Basic period.* Each hospice program as defined in section 1861(dd) of the Act is subject to a standard survey by an appropriate State or local survey agency, or an approved accreditation agency, as determined by the Secretary, not less frequently than once every 36 months. Additionally, a survey may be conducted as frequently as necessary to - ( 1 ) Assure the delivery of quality hospice program services by determining whether a hospice program complies with the Act and conditions of participation; and
( 2 ) Confirm that the hospice program has corrected deficiencies that were previously cited.
( b ) *Complaints.* A standard survey, or abbreviated standard survey- ( 1 ) Must be conducted of a hospice program when complaints against the hospice program are reported to CMS, the State, or local agency.
( 2 ) The State, or local agency is responsible for maintaining a toll-free hotline to collect, maintain, and continually update information on Medicare-participating hospice programs including significant deficiencies found regarding patient care, corrective actions, and remedy activity during its most recent survey, and to receive complaints and answer questions about hospice programs. The State or local agency is also responsible for maintaining a unit for investigating such complaints.
#### CORAL ISLE WEST CONDOMINIUM, Appellant, v. Arthur I. SNYDER, as Trustee, et al., Appellees.

No. 80-2474.

District Court of Appeal of Florida, Third District.

June 23, 1981.

Martin L. Carlin and Gerald Forman, Miami, for appellant.

Lapidus & Stettin and Herbert Stettin, Miami, for appellees.

Before BARKDULL, HENDRY and PEARSON, DANIEL S., JJ.

PER CURIAM.

Reversed on the authority of *Coral Isle East Condominium v. Snyder,*395 So.2d 1204 (Fla.3d DCA 1981), *cert. pending,*No. 60-608 (Fla., filed May 11, 1981).
HomeEnergy

# Energy

82 items

        -    Remarks  		Special Presidential Envoy for Climate John Kerry Delivers Opening Remarks at Virtual Leaders Summit on Climate, Session Two: Investing in Climate Solutions	  John KerryApril 22, 2021White House - Washington, DC 
        -    Fact Sheet  		Bureau of Energy Resources: Clean Energy Diplomacy on Climate	  April 22, 2021 
        -    Remarks  		Remarks at the 7th Berlin Energy Transition Dialogue	  John KerryMarch 15, 2021 
        -    Remarks  		Fireside Chat at IHS CERAWeek	  John KerryMarch 2, 2021 
        -    Remarks  		Remarks at World Sustainable Development Summit 2021	  John KerryFebruary 10, 2021World Sustainable Development Summit 2021 
        -    		CAATSA/CRIEEA Section 232 Public Guidance	   
        -    		CAATSA/CRIEEA Section 225 Public Guidance	   
        -    		Caribbean Energy Security Initiative (CESI)	   
        -    		Key Topics – Bureau of Energy Resources	   
        -    		CAATSA/CRIEEA Section 232 Public Guidance	  October 31, 2017 

previous page1…6789next page

Back to Top
Exhibit 10.18


 


Fees to be Paid to the Non-Management
Directors


of Sealed Air Corporation (the “Corporation”)


2009


 


Members of the
Board of Directors who are not officers or employees of the Corporation or any
subsidiary of the Corporation (“non-employee directors”) shall be paid the
following directors’ fees in cash, payable quarterly in arrears on or about the
first day of the succeeding calendar quarter, which fees shall be in addition
to retainers payable to non-employee directors under the Sealed Air Corporation
2002 Stock Plan for Non-Employee Directors:


 


(i)                                     a
fee of One Thousand Five Hundred Dollars ($1,500) for each meeting of the Board
of Directors or any committee of the Board of Directors attended by a
non-employee director that is held in person, regardless of whether the
non-employee director attends an in-person meeting by conference telephone or
similar communications equipment;


 


(ii)                                  a
fee of Seven Hundred Fifty Dollars ($750) for each meeting of the Board of
Directors or any committee of the Board of Directors attended by a non-employee
director that is held by conference telephone or similar communications
equipment;


 


(iii)                               for
each non-employee director who is a member of the Audit Committee, the
Nominating and Corporate Governance Committee or the Organization and
Compensation Committee of the Board of Directors, a fee of Five Hundred Dollars
($500) per calendar quarter for serving as a member;


 


(iv)                              for
each non-employee director who is designated as chairman of the Audit
Committee, a fee of One Thousand Dollars ($1,000) per calendar quarter for
serving as chairman;


 


(v)                                 for
each non-employee director who is designated as chairman of the Nominating and
Corporate Governance Committee or of the Organization and Compensation
Committee, a fee of Five Hundred Dollars ($500) per calendar quarter for
serving as chairman; and


 


(vi)                              a
fee of Two Thousand Dollars ($2,000) per day for special assignments undertaken
by a non-employee director at the request of the Board or any committee of the
Board or for attending a director education program.


 


The amount of
the Annual Retainer (as defined in the Sealed Air Corporation 2002 Stock Plan
for Non-Employee Directors) to be paid to Non-Employee Directors of the
Corporation who are elected at the 2009 Annual Meeting of Stockholders is
$90,000.


 


Under the Sealed Air
Corporation Deferred Compensation Plan for Directors, a non-employee director
may elect to defer all or part of his or her Annual Retainer (or Interim
Retainer, if the director joins the Board at a date other than the date of an
Annual Meeting) until the director retires from the Board. None of the other
fees mentioned above are eligible to be deferred.
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                                  SECTION 906,
                        OF THE SARBANES-OXLEY ACT OF 2002

         In  connection  with  the  Quarterly  Report  on  Form  10-Q  of  Enzon
Pharmaceuticals,  Inc.  (the  "Company")  for the period ended March 31, 2005 as
filed with the  Securities  and  Exchange  Commission  on the date  hereof  (the
"Report"), I, Toni L. Klich, Controller of the Company, certify to my knowledge,
pursuant to 18 U.S.C.  Section 1350,  as adopted  pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:


     1.   The Report fully  complies with the  requirements  of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     2.   The  information  contained  in the  Report  fairly  presents,  in all
          material respects,  the financial  condition and results of operations
          of the Company.



May 10, 2005            By:  /s/ TONI L. KLICH
                             -------------------------------------
                                Controller
                                (Acting Principal Accounting Officer)


                                       31
§ 424.545 Provider and supplier appeal rights. ( a ) *General.* A prospective provider or supplier that is denied enrollment in the Medicare program, or a provider or supplier whose Medicare enrollment has been revoked may appeal CMS' decision in accordance with part 498, subpart A of this chapter. ( 1 ) *Appeals resulting in the termination of a provider agreement.* ( i ) When revocation of billing privileges also results in the termination of a corresponding provider agreement, the provider may appeal CMS' decision in accordance with part 498 of this chapter with the final decision of the appeal applying to both the billing privileges and the provider agreement.
( ii ) When a provider appeals the revocation of billing privileges and the termination of its provider agreement, there will be one appeals process which will address both matters. The appeal procedures for revocation of Medicare billing privileges will apply.
( 2 ) *Payment of unpaid claims.* Payment is not made during the appeals process. If the provider or supplier is successful in overturning a denial or revocation, unpaid claims for services furnished during the overturned period may be resubmitted.
( b ) A provider or supplier whose billing privileges are deactivated may file a rebuttal in accordance with § 424.546 of this chapter.
( c ) The provider or supplier must be able to demonstrate that it meets the enrollment requirements and it must be able to make available any documents and records that support the provisions of this regulation and the Medicare enrollment application if requested by CMS or its agents.
[71 FR 20776, Apr. 21, 2006, as amended at 73 FR 36461, June 27, 2008; 86 FR 65683, Nov. 19, 2021]
HomeCertain Iranian Assets (Islamic Republic of Iran v. United States of America)...Order of July 1, 2016

# 									Order of July 1, 2016							

Office of the Assistant Legal Adviser for International Claims and Investment Disputes

July 1, 2016

Download Order						 [292 KB]

Back to Top
§ 456.143 Content of medical care evaluation studies. Each medical care evaluation study must— ( a ) Identify and analyze medical or administrative factors related to the hospital's patient care;
( b ) Include analysis of at least the following: ( 1 ) Admissions;
( 2 ) Durations of stay;
( 3 ) Ancillary services furnished, including drugs and biologicals;
( 4 ) Professional services performed in the hospital; and
( c ) If indicated, contain recommendations for changes beneficial to patients, staff, the hospital, and the community.
<TABLE> <S> <C>

<ARTICLE>       5
<MULTIPLIER>    1,000,000
<CIK>           0000727742
<NAME>          JSCE, INC.

<S>                        <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>         DEC-31-1999
<PERIOD-START>            JAN-01-1999
<PERIOD-END>              JUN-30-1999
<CASH>                             28
<SECURITIES>                        0
<RECEIVABLES>                     344
<ALLOWANCES>                        9
<INVENTORY>                       241
<CURRENT-ASSETS>                  704
<PP&E>                          2,352
<DEPRECIATION>                    881
<TOTAL-ASSETS>                  3,135
<CURRENT-LIABILITIES>             592
<BONDS>                         2,522
<COMMON>                            0
<PREFERRED-MANDATORY>               0
<PREFERRED>                         0
<OTHER-SE>                       (529)
<TOTAL-LIABILITY-AND-EQUITY>    3,135
<SALES>                         1,515
<TOTAL-REVENUES>                1,515
<CGS>                           1,279
<TOTAL-COSTS>                   1,279
<OTHER-EXPENSES>                  174
<LOSS-PROVISION>                    0
<INTEREST-EXPENSE>                 93
<INCOME-PRETAX>                   (31)
<INCOME-TAX>                       12
<INCOME-CONTINUING>               (19)
<DISCONTINUED>                      3
<EXTRAORDINARY>                     0
<CHANGES>                           0
<NET-INCOME>                      (16)
<EPS-BASIC>                     .00
<EPS-DILUTED>                     .00




</TABLE>
###### Editorial Note on Part 460

#### Editorial Note:

Nomenclature changes to part 460 appear at 67 FR 61504, Oct. 1, 2002.

#### § 460.198 Disclosure of compliance deficiencies.

CMS may require a PACE organization to disclose to its PACE participants or potential PACE participants the PACE organization's performance and contract compliance deficiencies in a manner specified by CMS.

[89 FR 30848, Apr. 23, 2024]
§ 493.803 Condition: Successful participation. ( a ) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA.
( b ) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part.
( c ) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: ( 1 ) There is immediate jeopardy to patient health and safety.
( 2 ) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance.
( 3 ) The laboratory has a poor compliance history.
[57 FR 7146, Feb. 28, 1992, as amended at 60 FR 20048, Apr. 24, 1995; 63 FR 26737, May 14, 1998; 68 FR 3702, Jan. 24, 2003]
Exhibit
      32.1











Written
      Statement of Chief Executive Officer


Pursuant
      to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002








The
      undersigned, the Chief Executive Officer of The Wilber Corporation (the
      "Company"), hereby certifies that to his knowledge on the date
      hereof:





(a)
            the
                Form 10-K of the Company for the Annual Period Ended December 31,
                2006,
                filed on the date hereof with the Securities and Exchange Commission
                (the
                "Report"), fully complies with the requirements of Section 13(a)
                or 15(d)
                of the Securities Exchange Act of 1934;
                and





(b)
            information
                contained in the Report fairly presents, in all material respects,
                the
                financial condition and results of operations of the
                Company.








/s/
                Douglas C. GulottyDouglas
                C. GulottyPresident
                and Chief Executive OfficerDate:March
                12, 2007





A
      signed
      original of this written statement required by Section 906, or other document
      authenticating, acknowledging, or otherwise adopting the signature that appears
      in typed form within the electronic version of this written statement required
      by Section 906, has been provided to The Wilber Corporation and will be retained
      by The Wilber Corporation and furnished to the Securities and Exchange
      Commission or its staff upon request.








92-K